Effects of 12-Week Equol Supplementation on Vascular Health in Postmenopausal Women With Chronic Kidney Disease

What this Trial Is About

This research aims to evaluate the effects of oral equol supplementation on vascular function in postmenopausal women with chronic kidney disease CKD. Women with CKD face a higher risk of cardiovascular disease CVD, partly due to vascular dysfunction and reduced protective hormones after menopause. The study addresses the gap in understanding vascular health in women with CKD, focusing on a potential new therapy to improve vascular function and reduce CVD risk. Participants are randomly assigned to one of two groups in this double-blind, placebo-controlled trial. One group receives 10 mg of equol daily two capsules of 5 mg each for 12 weeks, while the other group receives placebo capsules. The study tests the longer-term effects of equol supplementation on vascular health compared to placebo. During the study, participants will undergo assessments at baseline and after 12 weeks, including measurements of brachial artery flow-mediated dilation FMDBA, carotid-femoral pulse wave velocity CFPWV, and casual blood pressure. Researchers will monitor vascular function changes and safety throughout the trial. The total participation time spans the 12-week supplementation period with these specific vascular function evaluations.

Equol and Vascular Function in Women With Chronic Kidney Disease